Developing as a significant advance in the fight against obesity, the drug is generating considerable buzz. This treatment combines the action of two established GLP-1 receptor agonists, semaglutide , with an new glucose-dependent peptide component. Initial study results have demonstrated impressive weight loss in people with excessive weight, pot